Bibliography
- Alström Syndrome UK. Available from: http://www.alstrom.org.uk [Accessed 16 April 2014]
- Lysogene, a gene therapy biotechnology company. Available from: http://www.lysogene.com/en [Accessed 16 April 2014]
- Alkaptonuria Society. Available from: http://www.akusociety.org [Accessed 16 April 2014]
- EURORDIS, a non-governmental alliance of patient organisations. Available from: http://www.eurordis.org [Accessed 16 April 2014]
- Findacure, a charity builing the fundamental disease community to drive research and develop treatments. Available from: http://www.findacure.org.uk [Accessed 16 April 2014]
- Findacure’s campaign page on a crowdfunding platform. Available from: https://www.indiegogo.com/projects/fundamental-diseases-it-s-time-to-care [active from 28 April 2014 until 17 June 2014]
- Provost G. "Homeless" or "orphan" drugs. Am J Hosp Pharm 1968;25(11):609
- Harvey W. Letter IX, to John Vlackveld, 24 April 1657. In: The circulation of the blood. Cosimo, New York; 2006. p. 200-1
- Kaplan FS. The key to the closet is the key to the kingdom: a common lesson of rare diseases. Orphan Dis Update 2006;24(3):1-9
- Timmis O, Hall AK. Fundamental diseases: treasure your exceptions. Innovations in Pharmaceutical Technology. 2014;49:12-14
- Discovery Partnerships with Academia (DPAc). Available from: http://dpac.gsk.com/ [Accessed 16 April 2014]
- Johnson & Johnson Innovation Centre. Available from: http://www.jnj.com/partners/innovation-centers [Accessed 16 April 2014]
- Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ 2014;348:g1445
- Clinical Development of Nitisinone for Alkaptonuria. Available from: http://cordis.europa.eu/project/rcn/106157_en.html [Accessed 16 April 2014]